Non-Invasive Clinical Testing Using Biosensors

使用生物传感器进行非侵入性临床测试

• 批准号: 6740473
• 负责人: RICHARD G WOODBURY
• 金额: $ 9.65万
• 依托单位: BIOHESION, INC.
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-09-01 至 2005-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6740473
• 关键词: albumins; bioengineering /biomedical engineering; biomedical equipment development; biosensor device; clinical biomedical equipment; clinical research; diagnosis design /evaluation; diagnostic tests; human tissue; immunoglobulin A; noninvasive diagnosis; patient oriented research; saliva; surface plasmon resonance; surface property; urinalysis; urine

DESCRIPTION (provided by applicant): The development of non-invasive clinical diagnostics is a significant goal for improving healthcare. There is increasing awareness that specific diagnostics designed to test saliva and urine may be as predictive as conventional blood tests for many diseases and disorders. Ideally, future testing of saliva and urine will be rapid, quantitative and capable of continuous monitoring when appropriate. Biosensor instrumentation coupled with novel diagnostic assays offers great promise in this area provided there is progress in addressing several technical problems. BioHesion, Inc. will use proprietary protocols in the proposed feasibility research to achieve the following goals: 1) Development of diagnostic tests to quantify total slgA and albumin in saliva and urine using surface plasmon resonance detection. Testing is completed in 10-15min. Total slgA measurements in body secretions will be a requirement for tests to measure specific slgA in Phase II. 2) A significant reduction in biosensor fouling when testing saliva and urine. 3) An increase in the sensitivity of biosensing assays of at least 10-fold. 4) Increased durability of biosensing surfaces to permit repeated use or continuous monitoring of patients. The successful achievement of these goals will facilitate the implementation of mobile instruments capable of quantitative, non-invasive diagnostics at point-of testing. Ultimately, as the trend in sensor miniaturization continues, the robust assays developed in this project will be integrated with tiny sensors capable of continuous in vivo monitoring of patients.

描述（由申请人提供）：发展非侵入性临床诊断是改善医疗保健的重要目标。越来越多的人意识到，设计用于检测唾液和尿液的特定诊断方法可能与传统的血液检查一样，对许多疾病和失调具有预测性。理想情况下，未来的唾液和尿液检测将是快速、定量的，并且能够在适当的时候进行连续监测。如果在解决几个技术问题方面取得进展，生物传感器仪器与新型诊断分析相结合，在这一领域提供了巨大的希望。BioHesion, Inc.将在拟议的可行性研究中使用专有协议，以实现以下目标：